NASDAQ:AEON AEON Biopharma (AEON) Stock Price, News & Analysis $0.50 +0.06 (+14.71%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$0.51 +0.01 (+1.93%) As of 05/2/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About AEON Biopharma Stock (NASDAQ:AEON) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AEON Biopharma alerts:Sign Up Key Stats Today's Range$0.44▼$0.5050-Day Range$0.40▼$1.4252-Week Range$0.38▼$269.28Volume488,573 shsAverage Volume847,420 shsMarket Capitalization$5.28 millionP/E Ratio2.79Dividend YieldN/APrice Target$360.00Consensus RatingBuy Company OverviewAEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.Read More… AEON Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreAEON MarketRank™: AEON Biopharma scored higher than 35% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAEON Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAEON Biopharma has received no research coverage in the past 90 days.Read more about AEON Biopharma's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for AEON Biopharma are expected to grow in the coming year, from ($0.77) to ($0.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AEON Biopharma is 2.79, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.96.Price to Earnings Ratio vs. SectorThe P/E ratio of AEON Biopharma is 2.79, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 22.69.Read more about AEON Biopharma's valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for AEON. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAEON Biopharma does not currently pay a dividend.Dividend GrowthAEON Biopharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for AEON. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 2 people have searched for AEON on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added AEON Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, AEON Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.00% of the stock of AEON Biopharma is held by insiders.Percentage Held by InstitutionsOnly 22.78% of the stock of AEON Biopharma is held by institutions.Read more about AEON Biopharma's insider trading history. Receive AEON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AEON Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address AEON Stock News HeadlinesAEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing ComplianceApril 25, 2025 | globenewswire.comAEON Biopharma Announces Inducement Awards for New CEO Rob BancroftApril 23, 2025 | nasdaq.comThe Man I Turn to In Times Like ThisA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when publisher Brett Aitken turns to Whitney Tilson—a man CNBC once dubbed “The Prophet.” Tilson just released a new prediction that runs counter to what mainstream finance is telling you.May 3, 2025 | Stansberry Research (Ad)Aeon Biopharma appoints Rob Bancroft as CEOApril 21, 2025 | msn.comAEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711April 21, 2025 | globenewswire.comAEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive OfficerApril 21, 2025 | globenewswire.comBotulinum Toxin Market Forecast 2025-2030: Competitive Positioning, Strategies and Market Share AnalysisApril 14, 2025 | uk.finance.yahoo.comMineralys, Sana, Aeon: These 3 Biotech Stocks Saw The Sharpest Retail Interest Spike In Q1April 1, 2025 | msn.comSee More Headlines AEON Stock Analysis - Frequently Asked Questions How have AEON shares performed this year? AEON Biopharma's stock was trading at $38.88 at the start of the year. Since then, AEON stock has decreased by 98.7% and is now trading at $0.5013. View the best growth stocks for 2025 here. When did AEON Biopharma's stock split? AEON Biopharma's stock reverse split on Wednesday, February 26th 2025. The 1-72 reverse split was announced on Monday, February 24th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. When did AEON Biopharma IPO? AEON Biopharma (AEON) raised $75 million in an initial public offering on Thursday, October 14th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. How do I buy shares of AEON Biopharma? Shares of AEON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AEON Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that AEON Biopharma investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), Jabil (JBL), Disc Medicine (IRON), e.l.f. Beauty (ELF) and Adobe (ADBE). Company Calendar Today5/02/2025Next Earnings (Estimated)5/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AEON Previous SymbolNASDAQ:AEON CIK1837607 Webwww.aeonbiopharma.com Phone754-220-9229FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Stock Price Target$360.00 High Stock Price Target$360.00 Low Stock Price Target$360.00 Potential Upside/Downside+71,713.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$67.78 Trailing P/E Ratio2.79 Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,630,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-994.63% Debt Debt-to-Equity RatioN/A Current Ratio0.22 Quick Ratio0.22 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($4.12) per share Price / Book-0.12Miscellaneous Outstanding Shares10,533,000Free Float74,373,000Market Cap$5.28 million OptionableNot Optionable Beta0.35 The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:AEON) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredMassive red flag about American consumerWhy is the U.S. Dollar suddenly crashing? Pundits on either side of the aisle have been warning that the U....Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AEON Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AEON Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.